Continue to convene the PAWG to provide advice to innovators prior to submission of PSPs/PIPs and communicate technical opinions to SRAs in a timely manner.

WHO

-

Sub-action on-going

PAWG will communicate dosing and ratio for DTG/ABC/3TC and DTG/XTC/TAF as soon as individual dosing are confirmed

-

-

-

PAWG to review PIPs to provide feedback on alignment with PADO, prioritization and timelines

WHO

WHO/PAWG sent a letter to EMA including considerations for implementation of existing PIPs. Letter includes feedback from PAWG on PIPs for EMA. The messages of the letter will be communicated to relevant companies on dedicated calls with PAWG members to facilitate dialogue. PAWG members will remain available to discuss specific products with relevant innovators.

​

These considérations were also shared with members of the FDA technical team.

​

​

Milestone on-going

​

PSPs not publicly available for review

Provide dosing and ratio recommendations to generics for development of new FDCs.

WHO

-

-

-

-

-

-

-

-

-

-